Your browser doesn't support javascript.
loading
Bridging the gap - estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel.
Harries, Manuela; Jaeger, Veronika K; Rodiah, Isti; Hassenstein, Max J; Ortmann, Julia; Dreier, Maren; von Holt, Isabell; Brinkmann, Melanie; Dulovic, Alex; Gornyk, Daniela; Hovardovska, Olga; Kuczewski, Christina; Kurosinski, Marc-André; Schlotz, Maike; Schneiderhan-Marra, Nicole; Strengert, Monika; Krause, Gérard; Sester, Martina; Klein, Florian; Petersmann, Astrid; Karch, André; Lange, Berit.
Afiliación
  • Harries M; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany; Institute for Epidemiology Social Medicine and Health Systems Research, Hannover Medical School (MHH) Hannover, Germany. Electronic address: Manuela.Harries@helmholtz-hzi.de.
  • Jaeger VK; Institute of Epidemiology and Social Medicine, University of Münster, Germany.
  • Rodiah I; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Hassenstein MJ; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Ortmann J; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Dreier M; Institute for Epidemiology Social Medicine and Health Systems Research, Hannover Medical School (MHH) Hannover, Germany.
  • von Holt I; Institute for Epidemiology Social Medicine and Health Systems Research, Hannover Medical School (MHH) Hannover, Germany.
  • Brinkmann M; Institute for Epidemiology Social Medicine and Health Systems Research, Hannover Medical School (MHH) Hannover, Germany.
  • Dulovic A; NMI Natural and Medical Sciences, Institute at the University of Tubingen Reutlingen, Germany.
  • Gornyk D; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Hovardovska O; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Kuczewski C; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Kurosinski MA; Institute of Epidemiology and Social Medicine, University of Münster, Germany.
  • Schlotz M; Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne University of Cologne Cologne, Germany.
  • Schneiderhan-Marra N; NMI Natural and Medical Sciences, Institute at the University of Tubingen Reutlingen, Germany.
  • Strengert M; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany.
  • Krause G; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany; German Center for Infection Research (DZIF), Braunschweig, Germany.
  • Sester M; Department of transplant and infection immunology, Saarland University, Germany.
  • Klein F; Laboratory of Experimental Immunology, Institute of Virology Faculty of Medicine and University Hospital Cologne University of Cologne Cologne, Germany; German Center for Infection Research, Partner site Bonn-Cologne Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Colog
  • Petersmann A; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald Greifswald, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg Oldenburg, Germany.
  • Karch A; Institute of Epidemiology and Social Medicine, University of Münster, Germany.
  • Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research Braunschweig, Germany; German Center for Infection Research (DZIF), Braunschweig, Germany.
Int J Infect Dis ; 139: 50-58, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38008353
ABSTRACT

OBJECTIVES:

Throughout the SARS-CoV-2 pandemic, Germany like other countries lacked adaptive population-based panels to monitor the spread of epidemic diseases.

METHODS:

To fill a gap in population-based estimates needed for winter 2022/23 we resampled in the German SARS-CoV-2 cohort study MuSPAD in mid-2022, including characterization of systemic cellular and humoral immune responses by interferon-γ-release assay (IGRA) and CLIA/IVN assay. We were able to confirm categorization of our study population into four groups with differing protection levels against severe COVID-19 courses based on literature synthesis. Using these estimates, we assessed potential healthcare burden for winter 2022/23 in different scenarios with varying assumptions on transmissibility, pathogenicity, new variants, and vaccine booster campaigns in ordinary differential equation models.

RESULTS:

We included 9921 participants from eight German regions. While 85% of individuals were located in one of the two highest protection categories, hospitalization estimates from scenario modeling were highly dependent on viral variant characteristics ranging from 30-300% compared to the 02/2021 peak. Our results were openly communicated and published to an epidemic panel network and a newly established modeling network.

CONCLUSIONS:

We demonstrate feasibility of a rapid epidemic panel to provide complex immune protection levels for inclusion in dynamic disease burden modeling scenarios.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2024 Tipo del documento: Article